RESULTS BZDs are ineffective for PTSD treatment and prevention , and risks associated with their use tend to outweigh potential short-term benefits .
In addition to adverse effects in general population s , BZDs are associated with specific problems in patients with PTSD : worse overall severity , significantly increased risk of developing PTSD with use after recent trauma , worse psychotherapy outcomes , aggression , depression , and substance use .
The results of this systematic review suggest that BZDs should be considered relatively contraindicated for patients with PTSD or recent trauma .
OBJECTIVE Although benzodiazepines ( BZDs ) are commonly used in the treatment of posttraumatic stress disorder ( PTSD ) , no systematic review or meta- analysis has specifically examined this treatment .
The goal of this study was to analyze and summarize evidence concerning the efficacy of BZDs in treating PTSD .
A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans.
OBJECTIVE The authors examined the effectiveness of virtual reality exposure augmented with D-cycloserine or alprazolam , compared with placebo , in reducing  posttraumatic stress disorder ( PTSD ) due to military trauma . METHOD After an introductory session , five sessions of virtual reality exposure were augmented with D-cycloserine ( 50 mg ) or alprazolam ( 0.25 mg ) in a double-blind , placebo-controlled r and omized clinical trial for 156 Iraq and Afghanistan war veterans with PTSD . RESULTS PTSD symptoms significantly improved from pre- to posttreatment across all conditions and were maintained at 3 , 6 , and 12 months . There were no overall differences in symptoms between D-cycloserine and placebo at any time . Alprazolam and placebo differed significantly on the Clinician-Administered PTSD Scale score at posttreatment and PTSD diagnosis at 3 months posttreatment ; the alprazolam group showed a higher rate of PTSD ( 82.8 % ) than the placebo group ( 47.8 % ) . Between-session extinction learning was a treatment-specific enhancer of outcome for the D-cycloserine group only . At posttreatment , the D-cycloserine group had the lowest cortisol reactivity and smallest startle response during virtual reality scenes . CONCLUSIONS A six-session virtual reality treatment was associated with reduction in PTSD diagnoses and symptoms in Iraq and Afghanistan veterans , although there was no control condition for the virtual reality exposure . There was no advantage of D-cycloserine for PTSD symptoms in primary analyses . In secondary analyses , alprazolam impaired recovery and D-cycloserine enhanced virtual reality outcome in patients who demonstrated within-session learning . D-cycloserine augmentation reduced cortisol and startle reactivity more than did alprazolam or placebo , findings that are consistent with those in the animal literature
RESULTS BZDs are ineffective for PTSD treatment and prevention , and risks associated with their use tend to outweigh potential short-term benefits .
In addition to adverse effects in general population s , BZDs are associated with specific problems in patients with PTSD : worse overall severity , significantly increased risk of developing PTSD with use after recent trauma , worse psychotherapy outcomes , aggression , depression , and substance use .
The results of this systematic review suggest that BZDs should be considered relatively contraindicated for patients with PTSD or recent trauma .
OBJECTIVE Although benzodiazepines ( BZDs ) are commonly used in the treatment of posttraumatic stress disorder ( PTSD ) , no systematic review or meta- analysis has specifically examined this treatment .
The goal of this study was to analyze and summarize evidence concerning the efficacy of BZDs in treating PTSD .